International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 4 July-August 2024 Submit your research before last 3 days of August to publish your research paper in the issue of July-August.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 4
July-August 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

A Study of the Process of Identifying New Drugs and Enabling Ways

Author(s) Dr. Suryadevara Ramakrishna
Country India
Abstract The selection of clinical candidates, their synthesis, and characterization for therapeutic efficacy are all steps in the drug discovery process. This method underwent tremendous development over the past 50 years, beginning with a chemistry-centric approach and progressing through a more biological one to one that is more disease-specific. The development of molecular biology, along with improvements in screening and synthetic chemistry techniques, has made it possible to combine random screening with knowledge of the biological target. Although a strategic need drove this change, the astounding technological developments in chemistry and biology made it possible. The features of the new molecular entities will be refined during the course of numerous iterative screening runs required for this process, and the best balanced compounds will then move on to in vitro and in vivo testing in the selected disease model. 100 hits are thought to be found out of every 100,000 compounds tested. Only one of these 100 hits moves on to the lead compound stage. Most of these lead compounds—between 40% and 60%—fail ADMET testing. Despite the fact that the human genome project has revealed numerous unique and clinically verified targets in recent years, fewer new drugs are being launched, and the overall costs associated with developing a medicine are dramatically growing.
Keywords Drug, Medicine, Human, Compound
Field Chemistry
Published In Volume 5, Issue 5, September-October 2023
Published On 2023-10-04
Cite This A Study of the Process of Identifying New Drugs and Enabling Ways - Dr. Suryadevara Ramakrishna - IJFMR Volume 5, Issue 5, September-October 2023. DOI 10.36948/ijfmr.2023.v05i05.7206
DOI https://doi.org/10.36948/ijfmr.2023.v05i05.7206
Short DOI https://doi.org/gst3st
View / Download PDF File

Share this


E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com